How Can Implementation Science Improve the Care of Familial Hypercholesterolaemia?

"Declarations Conflict of InterestDr. Mitchell N. Sarkies reports financial support from a National Health and Medical Research Council Investigator Grant, and a Heart Foundation Vanguard Grant. Dr Sarkies reports honoraria related to speaker activities from Amgen.Dr. Laney Jones reports financial support from the National Institutes of Health. Dr Jones is a consultant for Novartis.Dr. Jing Pang reports financial support from a National Health and Medical Research Council Investigator Grant, and research funding grants from the Department of Health of Western Australia and the Royal Perth Hospital Research Foundation.Associate Professor David Sullivan reports honoraria related to consulting, research and/or speaker activities from Regeneron, Amgen, Ionis, AstraZeneca, Amarin, Esperion, and Novartis, as well as personal fees from Amgen, and Sanofi.Professor Gerald F Watts reports research support and/or honoraria for advisory boards from Amgen, Sanofi, Arrowhead, Novartis, Esperion, and AstraZeneca. Human and Animal Rights and Informed ConsentThis article does not contain any studies with human or animal subjects performed by any of the authors. Conflict of Interest Dr. Mitchell N. Sarkies reports financial support from a National Health and Medical Research Council Investigator Grant, and a Heart Foundation Vanguard Grant. Dr Sarkies reports honoraria related to speaker activities from Amgen. Dr. Laney Jones reports financial support from the National Institutes of Health. Dr Jones is a consultant for Novartis. Dr. Jing Pang reports financial support from a National Health and Medical Research Council Investigator Grant, and research funding grants from the Department of Health of Western Australia and the Royal Perth Hospital Research Foundation. Associate Professor David Sullivan reports honoraria related to consulting, research and/or speaker activities from Regeneron, Amgen, Ionis, AstraZeneca, Amarin, Esperion, and Novartis, as well as personal fees from Amgen, and Sanofi. Professor Gerald F Watts reports research support and/or honoraria for advisory boards from Amgen, Sanofi, Arrowhead, Novartis, Esperion, and AstraZeneca."

"Funding Open Access funding enabled and organized by CAUL and its Member Institutions"